Early steps of retrovirus replicative cycle

Retrovirology

Volumn 1, Issue , 2004, Pages

  Nisole, Sébastien ^b   Saïb, Ali ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLOPHILIN A; DNA BINDING PROTEIN; GAG PROTEIN; GENOMIC DNA; GENOMIC RNA; INTEGRASE; KARYOPHERIN ALPHA; LENS EPITHELIUM DERIVED GROWTH FACTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NEF PROTEIN; NUCLEOLIN; PROTEOHEPARAN SULFATE; RETROVIRUS VECTOR; REV PROTEIN; VIF PROTEIN; VIRUS CAPSID ANTIGEN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VPR PROTEIN; VIRUS RNA;

EQUINE INFECTIOUS ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; GENE TRANSFER; HEPATITIS B VIRUS; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS; LIFE CYCLE; MURINE LEUKEMIA VIRUS; NONHUMAN; PROVIRUS; REGULATORY MECHANISM; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; RNA TRANSCRIPTION; SIMIAN IMMUNODEFICIENCY VIRUS; SWINE INFLUENZA VIRUS; TARGET CELL; VIRUS CELL INTERACTION; VIRUS CORE; VIRUS DNA CELL DNA INTERACTION; VIRUS PARTICLE; VIRUS REPLICATION; VISNA VIRUS; ANIMAL; GENETICS; LIFE CYCLE STAGE; PHYSIOLOGY; VIRUS GENOME;

ANIMALS; DNA, VIRAL; GENOME, VIRAL; HUMANS; LIFE CYCLE STAGES; RETROVIRIDAE; RNA, VIRAL; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 4344652071     PISSN: 17424690     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-4690-1-9     Document Type: Review

References (265)

1. Amara A, Littman DR: After Hrs with HIV. J Cell Biol 2003, 162:371-375.
2. Perez OD, Nolan GP: Resistance is futile: assimilation of cellular machinery by HIV-1. Immunity 2001, 15:687-690.
3. Dvorin JD, Malim MH: Intracellular trafficking of HIV-1 cores: journey to the center of the cell. Curr Top Microbiol Immunol 2003, 281:179-208.
4. Goff SP: Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med 2001, 3:517-528.
5. Suomalainen M, Nakano MY, Keller S, Boucke K, Stidwill RP, Greber UF: Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. J Cell Biol 1999, 144:657-672.
6. Sodeik B, Ebersold MW, Helenius A: Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J Cell Biol 1997, 136:1007-1021.
7. Sherman MP, Greene WC: Slipping through the door: HIV entry into the nucleus. Microbes Infect 2002, 4:67-73.
8. Towers GJ, Goff SP: Post-entry restriction of retroviral infections. AIDS Rev 2003, 5:156-164.
9. Sharma S, Miyanohara A, Friedmann T: Separable mechanisms of attachment and cell uptake during retrovirus infection. J Virol 2000, 74:10790-10795.
10. Pizzato M, Marlow SA, Blair ED, Takeuchi Y: Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J Virol 1999, 73:8599-8611.
11. Ugolini S, Mondor I, Sattentau QJ: HIV-1 attachment: another look. Trends Microbiol 1999, 7:144-149.
12. Mondor I, Ugolini S, Sattentau QJ: Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998, 72:3623-3634.
13. Fortin JF, Cantin R, Tremblay MJ: T cells expressing activated LFA-1 are more susceptible to infection with human immunodeficiency virus type 1 particles bearing host-encoded ICAM-1. J Virol 1998, 72:2105-2112.
14. Nisole S, Krust B, Callebaut C, Guichard G, Muller S, Briand JP, Hovanessian AG: The anti-HIV pseudopeptide HB-19 forms a complex with the cell-surface-expressed nucleolin independent of heparan sulfate proteoglycans. J Biol Chem 1999, 274:27875-27884.
15. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992, 66:235-243.
16. O'Doherty U, Swiggard WJ, Malim MH: Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 2000, 74:10074-10080.
17. Spillmann D: Heparan sulfate: anchor for viral intruders? Biochimie 2001, 83:811-817.
18. Pinon JD, Klasse PJ, Jassal SR, Welson S, Weber J, Brighty DW, Sattentau QJ: Human T-cell leukemia virus type 1 envelope glycoprotein gp46 interacts with cell surface heparan sulfate proteoglycans. J Virol 2003, 77:9922-9930.
19. Walker SJ, Pizzato M, Takeuchi Y, Devereux S: Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J Virol 2002, 76:6909-6918.
20. Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD: Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol 2002, 76:6332-6343.
21. Guibinga GH, Miyanohara A, Esko JD, Friedmann T: Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol Ther 2002, 5:538-546.
22. Marechal V, Clavel F, Heard JM, Schwartz O: Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 1998, 72:2208-2212.
23. Schaeffer E, Soros VB, Greene WC: Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J Virol 2004, 78:1375-1383.
24. Pohlmann S, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, Trowsdale J, Lee B, Coleman N, Doms RW: DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans. Proc Natl Acad Sci U S A 2001, 98:2670-2675.
25. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
26. Hong PW, Flummerfelt KB, de Parseval A, Gurney K, Elder JH, Lee B: Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. J Virol 2002, 76:12855-12865.
27. Lin CL, Sewell AK, Gao GF, Whelan KT, Phillips RE, Austyn JM: Macrophage-tropic HIV induces and exploits dendritic cell chemotaxis. J Exp Med 2000, 192:587-594.
28. Lue J, Hsu M, Yang D, Marx P, Chen Z, Cheng-Mayer C: Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol 2002, 76:10299-10306.
29. Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Krieger E, Vriend G, Figdor CG, van Kooyk Y: Identification of different binding sites in the dendritic cell-specific receptor DC-SIGN for intercellular adhesion molecule 3 and HIV-1. J Biol Chem 2002, 277:11314-11320.
30. Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, Doms RW, Cunningham AL: Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 2002, 3:975-983.
31. van Kooyk Y, Geijtenbeek TB: DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 2003, 3:697-709.
32. Tailleux L, Schwartz O, Herrmann JL, Pivert E, Jackson M, Amara A, Legres L, Dreher D, Nicod LP, Gluckman JC, Lagrange PH, Gicquel B, Neyrolles O: DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. J Exp Med 2003, 197:121-127.
33. Kim JW, Closs EI, Albritton LM, Cunningham JM: Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. Nature 1991, 352:725-728.
34. Wang H, Kavanaugh MP, North RA, Kabat D: Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter. Nature 1991, 352:729-731.
35. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, Axel R: The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986, 47:333-348.
36. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL: The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115:449-459.
37. O'Hara B, Johann SV, Klinger HP, Blair DG, Rubinson H, Dunn KJ, Sass P, Vitek SM, Robins T: Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ 1990, 1:119-127.
38. van Zeijl M, Johann SV, Closs E, Cunningham J, Eddy R, Shows TB, O'Hara B: A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family. Proc Natl Acad Sci U S A 1994, 91:1168-1172.
39. Miller DG, Miller AD: A family of retroviruses that utilize related phosphate transporters for cell entry. J Virol 1994, 68:8270-8276.
40. Hill CL, Bieniasz PD, McClure MO: Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol 1999, 80(Pt 8):2003-2009.
41. Mergia A, Heinkelein M: Foamy virus vectors. Curr Top Microbiol Immunol 2003, 277:131-159.
42. von Laer D, Neumann-Haefelin D, Heeney JL, Schweizer M: Lymphocytes are the major reservoir for foamy viruses in peripheral blood. Virology 1996, 221:240-244.
43. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999, 17:657-700.
44. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
45. Gallo SA, Finnegan CM, Viard M, Raviv Y, Dimitrov A, Rawat SS, Puri A, Durell S, Blumenthal R: The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003, 1614:36-50.
46. Moore JP, Doms RW: The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 2003, 100:10598-10602.
47. Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg DH, Gonzalez-Scarano F: Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 1991, 253:320-323.
48. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997, 387:569-572.
49. Hammache D, Yahi N, Maresca M, Pieroni G, Fantini J: Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3). J Virol 1999, 73:5244-5248.
50. Manes S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C, Sanchez-Palomino S, Delgado R, Alcami J, Mira E, Martinez AC: Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000, 1:190-196.
51. Del Real G, Jimenez-Baranda S, Lacalle RA, Mira E, Lucas P, Gomez-Mouton C, Carrera AC, Martinez AC, Manes S: Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002, 196:293-301.
52. Popik W, Alce TM, Au WC: Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4(+) T cells. J Virol 2002, 76:4709-4722.
53. Nisole S, Krust B, Hovanessian AG: Anchorage of HIV on permissive cells leads to coaggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res 2002, 276:155-173.
54. Percherancier Y, Lagane B, Planchenault T, Staropoli I, Altmeyer R, Virelizier JL, Arenzana-Seisdedos F, Hoessli DC, Bachelerie F: HIV-1 entry into T-cells is not dependent on CD4 and CCR5 localization to sphingolipid-enriched, detergent-resistant, raft membrane domains. J Biol Chem 2003, 278:3153-3161.
55. Popik W, Alce TM: CD4 receptor localized to non-raft membrane microdomains supports HIV-1 entry. Identification of a novel raft localization marker in CD4. J Biol Chem 2004, 279:704-712.
56. Nguyen DH, Hildreth JE: Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000, 74:3264-3272.
57. Aloia RC, Tian H, Jensen FC: Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A 1993, 90:5181-5185.
58. Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D: Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 2002, 76:10356-10364.
59. McClure MO, Marsh M, Weiss RA: Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. Embo J 1988, 7:513-518.
60. Schwartz O, Marechal V, Friguet B, Arenzana-Seisdedos F, Heard JM: Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. J Virol 1998, 72:3845-3850.
61. Fredericksen BL, Wei BL, Yao J, Luo T, Garcia JV: Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus. J Virol 2002, 76:11440-11446.
62. Katen LJ, Januszeski MM, Anderson WF, Hasenkrug KJ, Evans LH: Infectious entry by amphotropic as well as ecotropic murine leukemia viruses occurs through an endocytic pathway. J Virol 2001, 75:5018-5026.
63. Picard-Maureau M, Jarmy G, Berg A, Rethwilm A, Lindemann D: Foamy virus envelope glycoprotein-mediated entry involves a pH-dependent fusion process. J Virol 2003, 77:4722-4730.
64. Kizhatil K, Albritton LM: Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion. J Virol 1997, 71:7145-7156.
65. Skehel JJ, Wiley DC: Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569.
66. Mothes W, Boerger AL, Narayan S, Cunningham JM, Young JA: Retroviral entry mediated by receptor priming and low pH triggering of an envelope glycoprotein. Cell 2000, 103:679-689.
67. Sanders RW, de Jong EC, Baldwin CE, Schuitemaker JH, Kapsenberg ML, Berkhout B: Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol 2002, 76:7812-7821.
68. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ: Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297.
69. Pelchen-Matthews A, Kramer B, Marsh M: Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 2003, 162:443-455.
70. Telesnitsky A, Goff SP: Reverse transcriptase and the generation of retroviral DNA. In Retroviruses (Edited by: Coffin JM, Hughes SH, Varmus HE). Cold Spring Harbor Laboratory Press 1997, 121-160.
71. Lori F, di Marzo Veronese F, de Vico AL, Lusso P, Reitz Jr MS, Gallo RC: Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol 1992, 66:5067-5074.
72. Trono D: Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol 1992, 66:4893-4900.
73. Zhu J, Cunningham JM: Minus-strand DNA is present within murine type C ecotropic retroviruses prior to infection. J Virol 1993, 67:2385-2388.
74. Yu SF, Sullivan MD, Linial ML: Evidence that the human foamy virus genome is DNA. J Virol 1999, 73:1565-1572.
75. Moebes A, Enssle J, Bieniasz PD, Heinkelein M, Lindemann D, Bock M, McClure MO, Rethwilm A: Human foamy virus reverse transcription that occurs late in the viral replication cycle. J Virol 1997, 71:7305-7311.
76. Delelis O, Saib A, Sonigo P: Biphasic DNA synthesis in spumaviruses. J Virol 2003, 77:8141-8146.
77. Lecellier CH, Saib A: Foamy viruses: between retroviruses and pararetroviruses. Virology 2000, 271:1-8.
78. Zhang H, Dornadula G, Orenstein J, Pomerantz RJ: Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. J Hum Virol 2000, 3:165-172.
79. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ: Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002, 159:441-452.
80. Kimpton J, Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992, 66:2232-2239.
81. Piatak Jr M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
82. Andreadis S, Lavery T, Davis HE, Le Doux JM, Yarmush ML, Morgan JR: Toward a more accurate quantitation of the activity of recombinant retroviruses: alternatives to titer and multiplicity of infection. J Virol 2000, 74:3431-3439.
83. Bukrinskaya A, Brichacek B, Mann A, Stevenson M: Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J Exp Med 1998, 188:2113-2125.
84. Fassati A, Gorlich D, Harrison I, Zaytseva L, Mingot JM: Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. Embo J 2003, 22:3675-3685.
85. Fassati A, Goff SP: Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 2001, 75:3626-3635.
86. Miller MD, Farnet CM, Bushman FD: Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997, 71:5382-5390.
87. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M: Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci U S A 1993, 90:6125-6129.
88. Farnet CM, Bushman FD: HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 1997, 88:483-492.
89. Risco C, Menendez-Arias L, Copeland TD, Pinto da Silva P, Oroszlan S: Intracellular transport of the murine leukemia virus during acute infection of NIH 3T3 cells: nuclear import of nucleocapsid protein and integrase. J Cell Sci 1995, 108(Pt 9):3039-3050.
90. Fassati A, Goff SP: Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. J Virol 1999, 73:8919-8925.
91. Petit C, Giron ML, Tobaly-Tapiero J, Bittoun P, Real E, Jacob Y, Tordo N, De The H, Saib A: Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J Cell Sci 2003, 116:3433-3442.
92. Saib A, Puvion-Dutilleul F, Schmid M, Peries J, de The H: Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step. J Virol 1997, 71:1155-1161.
93. Ojala PM, Sodeik B, Ebersold MW, Kutay U, Helenius A: Herpes simplex virus type 1 entry into host cells: reconstitution of capsid binding and uncoating at the nuclear pore complex in vitro. Mol Cell Biol 2000, 20:4922-4931.
94. Greber UF, Suomalainen M, Stidwill RP, Boucke K, Ebersold MW, Helenius A: The role of the nuclear pore complex in adenovirus DNA entry. Embo J 1997, 16:5998-6007.
95. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF: Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol 2001, 3:1092-1100.
96. Jamieson BD, Aldrovandi GM, Planelles V, Jowett JB, Gao L, Bloch LM, Chen IS, Zack JA: Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol 1994, 68:3478-3485.
97. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC: Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 1994, 68:2906-2914.
98. Miller MD, Feinberg MB, Greene WC: The HIV-1 nef gene acts as a positive viral infectivity factor. Trends Microbiol 1994, 2:294-298.
99. Aiken C, Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995, 69:5048-5056.
100. Aiken C: Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J Virol 1997, 71:5871-5877.
101. Schaeffer E, Geleziunas R, Greene WC: Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 2001, 75:2993-3000.
102. Luo T, Douglas JL, Livingston RL, Garcia JV: Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 1998, 241:224-233.
103. Zheng YH, Plemenitas A, Fielding CJ, Peterlin BM: Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A 2003, 100:8460-8465.
104. von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993, 67:4945-4955.
105. Ohagen A, Gabuzda D: Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol 2000, 74:11055-11066.
106. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003, 300:1112.
107. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
108. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003, 9:1398-1403.
109. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003, 9:1404-1407.
110. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
111. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP: Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73:1067-1078.
112. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Gottlinger HG: Functional association of cyclophilin A with HIV-1 virions. Nature 1994, 372:363-365.
113. Gamble TR, Vajdos FF, Yoo S, Worthylake DK, Houseweart M, Sundquist WI, Hill CP: Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 1996, 87:1285-1294.
114. Braaten D, Franke EK, Luban J: Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol 1996, 70:3551-3560.
115. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD: Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003, 9:1138-1143.
116. Butera ST, Perez VL, Besansky NJ, Chan WC, Wu BY, Nabel GJ, Folks TM: Extrachromosomal human immunodeficiency virus type-1 DNA can initiate a spreading infection of HL-60 cells. J Cell Biochem 1991, 45:366-373.
117. Stevenson M, Haggerty S, Lamonica CA, Meier CM, Welch SK, Wasiak AJ: Integration is not necessary for expression of human immunodeficiency virus type 1 protein products. J Virol 1990, 64:2421-2425.
118. Teo I, Veryard C, Barnes H, An SF, Jones M, Lantos PL, Luthert P, Shaunak S: Circular forms of unintegrated human immunodeficiency virus type 1 DNA and high levels of viral protein expression: association with dementia and multinucleated giant cells in the brains of patients with AIDS. J Virol 1997, 71:2928-2933.
119. Cara A, Cereseto A, Lori F, Reitz Jr MS: HIV-1 protein expression from synthetic circles of DNA mimicking the extrachromosomal forms of viral DNA. J Biol Chem 1996, 271:5393-5397.
120. Wu Y, Marsh JW: Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol 2003, 77:10376-10382.
121. Poon B, Chen IS: Human immunodeficiency virus type 1 (HIV-1) Vpr enhances expression from unintegrated HIV-1 DNA. J Virol 2003, 77:3962-3972.
122. Ploubidou A, Way M: Viral transport and the cytoskeleton. Curr Opin Cell Biol 2001, 13:97-105.
123. Ploubidou A, Moreau V, Ashman K, Reckmann I, Gonzalez C, Way M: Vaccinia virus infection disrupts microtubule organization and centrosome function. Embo J 2000, 19:3932-3944.
124. Rietdorf J, Ploubidou A, Reckmann I, Holmstrom A, Frischknecht F, Zettl M, Zimmermann T, Way M: Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat Cell Biol 2001, 3:992-1000.
125. de Soultrait VR, Caumont A, Durrens P, Calmels C, Parissi V, Recordon P, Bon E, Desjobert C, Tarrago-Litvak L, Fournier M: HIV-1 integrase interacts with yeast microtubule-associated proteins. Biochim Biophys Acta 2002, 1575:40-48.
126. Ibarrondo FJ, Choi R, Geng YZ, Canon J, Rey O, Baldwin GC, Krogstad P: HIV type 1 Gag and nucleocapsid proteins: cytoskeletal localization and effects on cell motility. AIDS Res Hum Retroviruses 2001, 17:1489-1500.
127. Liu B, Dai R, Tian CJ, Dawson L, Gorelick R, Yu XF: Interaction of the human immunodeficiency virus type 1 nucleocapsid with actin. J Virol 1999, 73:2901-2908.
128. Wilk T, Gowen B, Fuller SD: Actin associates with the nucleocapsid domain of the human immunodeficiency virus Gag polyprotein. J Virol 1999, 73:1931-1940.
129. Watts NR, Sackett DL, Ward RD, Miller MW, Wingfield PT, Stahl SS, Steven AC: HIV-1 rev depolymerizes microtubules to form stable bilayered rings. J Cell Biol 2000, 150:349-360.
130. Strebel K, Bour S: Molecular interactions of HIV with host factors. Aids 1999, 13(Suppl A):S13-24.
131. Alonso C, Miskin J, Hernaez B, Fernandez-Zapatero P, Soto L, Canto C, Rodriguez-Crespo I, Dixon L, Escribano JM: African swine fever virus protein p54 interacts with the microtubular motor complex through direct binding to light-chain dynein. J Virol 2001, 75:9819-9827.
132. Raux H, Flamand A, Blondel D: Interaction of the rabies virus P protein with the LC8 dynein light chain. J Virol 2000, 74:10212-10216.
133. Poisson N, Real E, Gaudin Y, Vaney MC, King S, Jacob Y, Tordo N, Blondel D: Molecular basis for the interaction between rabies virus phosphoprotein P and the dynein light chain LC8: dissociation of dynein-binding properties and transcriptional functionality of P. J Gen Virol 2001, 82:2691-2696.
134. Jacob Y, Badrane H, Ceccaldi PE, Tordo N: Cytoplasmic dynein LC8 interacts with lyssavirus phosphoprotein. J Virol 2000, 74:10217-10222.
135. Harrison A, King SM: The molecular anatomy of dynein. Essays Biochem 2000, 35:75-87.
136. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR: Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003, 299:1713-1716.
137. Sfakianos JN, Hunter E: M-PMV capsid transport is mediated by Env/Gag interactions at the pericentriolar recycling endosome. Traffic 2003, 4:671-680.
138. Sfakianos JN, LaCasse RA, Hunter E: The M-PMV cytoplasmic targeting-retention signal directs nascent Gag polypeptides to a pericentriolar region of the cell. Traffic 2003, 4:660-670.
139. Calafat J, Hilkens JG: Ultrastructural study of virus-like particles in Chinese hamster lung cells. J Gen Virol 1978, 41:417-420.
140. Heine UI, Kramarsky B, Wendel E, Suskind RG: Enhanced proliferation of endogenous virus in Chinese hamster cells associated with microtubules and the mitotic apparatus of the host cell. J Gen Virol 1979, 44:45-55.
141. Roe T, Reynolds TC, Yu G, Brown PO: Integration of murine leukemia virus DNA depends on mitosis. Embo J 1993, 12:2099-2108.
142. Lewis PF, Emerman M: Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994, 68:510-516.
143. Weinberg JB, Matthews TJ, Cullen BR, Malim MH: Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 1991, 174:1477-1482.
144. Bukrinsky MI, Sharova N, Dempsey MP, Stanwick TL, Bukrinskaya AG, Haggerty S, Stevenson M: Active nuclear import of human immunodeficiency virus type 1 preintegration complexes. Proc Natl Acad Sci U S A 1992, 89:6580-6584.
145. Hatziioannou T, Goff SP: Infection of nondividing cells by Rous sarcoma virus. J Virol 2001, 75:9526-9531.
146. Bieniasz PD, Weiss RA, McClure MO: Cell cycle dependence of foamy retrovirus infection. J Virol 1995, 69:7295-7299.
147. Pante N, Kann M: Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm. Mol Biol Cell 2002, 13:425-434.
148. Fried H, Kutay U: Nucleocytoplasmic transport: taking an inventory. Cell Mol Life Sci 2003, 60:1659-1688.
149. Cullen BR: Journey to the center of the cell. Cell 2001, 105:697-700.
150. Gallay P, Hope T, Chin D, Trono D: HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway. Proc Natl Acad Sci U S A 1997, 94:9825-9830.
151. Bouyac-Bertoia M, Dvorin JD, Fouchier RA, Jenkins Y, Meyer BE, Wu LI, Emerman M, Malim MH: HIV-1 infection requires a functional integrase NLS. Mol Cell 2001, 7:1025-1035.
152. Katz RA, Greger JG, Boimel P, Skalka AM: Human immunodeficiency virus type 1 DNA nuclear import and integration are mitosis independent in cycling cells. J Virol 2003, 77:13412-13417.
153. Dvorin JD, Bell P, Maul GG, Yamashita M, Emerman M, Malim MH: Reassessment of the roles of integrase and the central DNA flap in human immunodeficiency virus type 1 nuclear import. J Virol 2002, 76:12087-12096.
154. Limon A, Devroe E, Lu R, Ghory HZ, Silver PA, Engelman A: Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import. J Virol 2002, 76:10598-10607.
155. Depienne C, Mousnier A, Leh H, Le Rouzic E, Dormont D, Benichou S, Dargemont C: Characterization of the nuclear import pathway for HIV-1 integrase. J Biol Chem 2001, 276:18102-18107.
156. Devroe E, Engelman A, Silver PA: Intracellular transport of human immunodeficiency virus type 1 integrase. J Cell Sci 2003, 116:4401-4408.
157. Bukrinsky MI, Haggerty S, Dempsey MP, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M: A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993, 365:666-669.
158. von Schwedler U, Kornbluth RS, Trono D: The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A 1994, 91:6992-6996.
159. Reil H, Bukovsky AA, Gelderblom HR, Gottlinger HG: Efficient HIV-1 replication can occur in the absence of the viral matrix protein. Embo J 1998, 17:2699-2708.
160. Fouchier RA, Meyer BE, Simon JH, Fischer U, Malim MH: HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. Embo J 1997, 16:4531-4539.
161. Freed EO, Englund G, Martin MA: Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol 1995, 69:3949-3954.
162. Haffar OK, Popov S, Dubrovsky L, Agostini I, Tang H, Pushkarsky T, Nadler SG, Bukrinsky M: Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex. J Mol Biol 2000, 299:359-368.
163. Vodicka MA, Koepp DM, Silver PA, Emerman M: HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev 1998, 12:175-185.
164. Heinzinger NK, Bukinsky MI, Haggerty SA, Ragland AM, Kewalramani V, Lee MA, Gendelman HE, Ratner L, Stevenson M, Emerman M: The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc Natl Acad Sci U S A 1994, 91:7311-7315.
165. Popov S, Rexach M, Ratner L, Blobel G, Bukrinsky M: Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998, 273:13347-13352.
166. Popov S, Rexach M, Zybarth G, Reiling N, Lee MA, Ratner L, Lane CM, Moore MS, Blobel G, Bukrinsky M: Viral protein R regulates nuclear import of the HIV-1 pre-integration complex. Embo J 1998, 17:909-917.
167. Le Rouzic E, Mousnier A, Rustum C, Stutz F, Hallberg E, Dargemont C, Benichou S: Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem 2002, 277:45091-45098.
168. Fouchier RA, Meyer BE, Simon JH, Fischer U, Albright AV, Gonzalez-Scarano F, Malim MH: Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex. J Virol 1998, 72:6004-6013.
169. de Noronha CM, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC: Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 2001, 294:1105-1108.
170. Fletcher 3rd TM, Brichacek B, Sharova N, Newman MA, Stivahtis G, Sharp PM, Emerman M, Hahn BH, Stevenson M: Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). Embo J 1996, 15:6155-6165.
171. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P: HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000, 101:173-185.
172. Charneau P, Mirambeau G, Roux P, Paulous S, Buc H, Clavel F: HIV-1 reverse transcription. A termination step at the center of the genome. J Mol Biol 1994, 241:651-662.
173. Van Maele B, De Rijck J, De Clercq E, Debyser Z: Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol 2003, 77:4685-4694.
174. Limon A, Nakajima N, Lu R, Ghory HZ, Engelman A: Wild-type levels of nuclear localization and human immunodeficiency virus type 1 replication in the absence of the central DNA flap. J Virol 2002, 76:12078-12086.
175. Ao Z, Yao X, Cohen EA: Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system. J Virol 2004, 78:3170-3177.
176. Tobaly-Tapiero J, Kupiec JJ, Santillana-Hayat M, Canivet M, Peries J, Emanoil-Ravier R: Further characterization of the gapped DNA intermediates of human spumavirus: evidence for a dual initiation of plus-strand DNA synthesis. J Gen Virol 1991, 72(Pt 3):605-608.
177. Kupiec JJ, Tobaly-Tapiero J, Canivet M, Santillana-Hayat M, Flugel RM, Peries J, Emanoil-Ravier R: Evidence for a gapped linear duplex DNA intermediate in the replicative cycle of human and simian spumaviruses. Nucleic Acids Res 1988, 16:9557-9565.
178. Heyman T, Wilhelm M, Wilhelm FX: The central PPT of the yeast retrotransposon Ty1 is not essential for transposition. J Mol Biol 2003, 331:315-320.
179. Holzschu DL, Martineau D, Fodor SK, Vogt VM, Bowser PR, Casey JW: Nucleotide sequence and protein analysis of a complex piscine retrovirus, walleye dermal sarcoma virus. J Virol 1995, 69:5320-5331.
180. LaPierre LA, Holzschu DL, Bowser PR, Casey JW: Sequence and transcriptional analyses of the fish retroviruses walleye epidermal hyperplasia virus types 1 and 2: evidence for a gene duplication. J Virol 1999, 73:9393-9403.
181. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF: Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002, 76:4138-4144.
182. Serhan F, Penaud M, Petit C, Leste-Lasserre T, Trajcevski S, Klatzmann D, Duisit G, Sonigo P, Moullier P: Early detection of a 2-LTR junction molecule in the cytoplasm of recombinant murine leukemia virus-infected cells. J Virol 2004, in press.
183. Yamashita M, Emerman M: Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol 2004, 78:5670-5678.
184. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
185. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302:415-419.
186. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003, 348:255-256.
187. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ, Jenkins NA, Copeland NG: New genes involved in cancer identified by retroviral tagging. Nat Genet 2002, 32:166-174.
188. Pryciak PM, Sil A, Varmus HE: Retroviral integration into minichromosomes in vitro. Embo J 1992, 11:291-303.
189. Craigie R: Hotspots and warm spots: integration specificity of retroelements. Trends Genet 1992, 8:187-190.
190. Carteau S, Hoffmann C, Bushman F: Chromosome structure and human immunodeficiency virus type 1 cDNA integration: centromeric alphoid repeats are a disfavored target. J Virol 1998, 72:4005-4014.
191. Weidhaas JB, Angelichio EL, Fenner S, Coffin JM: Relationship between retroviral DNA integration and gene expression. J Virol 2000, 74:8382-8389.
192. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110:521-529.
193. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300:1749-1751.
194. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, Debyser Z, Engelborghs Y: LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003, 278:33528-33539.
195. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, De Clercq E, Debyser Z: HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 2003, 278:372-381.
196. Cherepanov P, Pluymers W, Claeys A, Proost P, De Clercq E, Debyser Z: High-level expression of active HIV-1 integrase from a synthetic gene in human cells. Faseb J 2000, 14:1389-1399.
197. Asante-Appiah E, Skalka AM: Molecular mechanisms in retrovirus DNA integration. Antiviral Res 1997, 36:139-156.
198. Shibagaki Y, Chow SA: Central core domain of retroviral integrase is responsible for target site selection. J Biol Chem 1997, 272:8361-8369.
199. Shibagaki Y, Holmes ML, Appa RS, Chow SA: Characterization of feline immunodeficiency virus integrase and analysis of functional domains. Virology 1997, 230:1-10.
200. Katzman M, Sudol M: Mapping domains of retroviral integrase responsible for viral DNA specificity and target site selection by analysis of chimeras between human immunodeficiency virus type 1 and visna virus integrases. J Virol 1995, 69:5687-5696.
201. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP: Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994, 266:2002-2006.
202. Mansharamani M, Graham DR, Monie D, Lee KK, Hildreth JE, Siliciano RF, Wilson KL: Barrier-to-autointegration factor BAF binds p55 Gag and matrix and is a host component of human immunodeficiency virus type 1 virions. J Virol 2003, 77:13084-13092.
203. Violot S, Hong SS, Rakotobe D, Petit C, Gay B, Moreau K, Billaud G, Priet S, Sire J, Schwartz O, Mouscadet JF, Boulanger P: The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J Virol 2003, 77:12507-12522.
204. Denisenko ON, Bomsztyk K: The product of the murine homolog of the Drosophila extra sex combs gene displays transcriptonal repressor activity. Mol Cell Biol 17:4707-4717.
205. Peytavi R, Hong SS, Gay B, d'Angeac AD, Selig L, Benichou S, Benarous R, Boulanger P: HEED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1. J Biol Chem 1999, 274:1635-1645.
206. SanMiguel P, Tikhonov A, Jin YK, Motchoulskaia N, Zakharov D, Melake-Berhan A, Springer PS, Edwards KJ, Lee M, Avramova Z, Bennetzen JL: Nested retrotransposons in the intergenic regions of the maize genome. Science 1996, 274:765-768.
207. Pardue ML, DeBaryshe PG: Retrotransposons provide an evolutionarily robust non-telomerase mechanism to maintain telomeres. Annu Rev Genet 2003, 37:485-511.
208. Zhu Y, Dai J, Fuerst PG, Voytas DF: Controlling integration specificity of a yeast retrotransposon. Proc Natl Acad Sci U S A 2003, 100:5891-5895.
209. Sandmeyer S: Targeting transposition: at home in the genome. Genome Res 1998, 8:416-418.
210. Sandmeyer S: Integration by design. Proc Natl Acad Sci U S A 2003, 100:5586-5588.
211. Bushman FD: Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell 2003, 115:135-138.
212. Bushman F: Targeting retroviral integration? Mol Ther 2002, 6:570-571.
213. Curcio MJ, Garfinkel DJ: New lines of host defense: inhibition of Ty1 retrotransposition by Fus3p and NER/TFIIH. Trends Genet 1999, 15:43-45.
214. Griffith JL, Coleman LE, Raymond AS, Goodson SG, Pittard WS, Tsui C, Devine SE: Functional genomics reveals relationships between the retrovirus-like Ty1 element and its host Saccharomyces cerevisiae. Genetics 2003, 164:867-879.
215. Bieniasz PD: Restriction factors: a defense against retroviral infection. Trends Microbiol 2003, 11:286-291.
216. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH: DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113:803-809.
217. Turelli P, Mangeat B, Jost S, Vianin S, Trono D: Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
218. Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003, 12:591-601.
219. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003, 77:11398-11407.
220. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
221. Chesebro B, Miyazawa M, Britt WJ: Host genetic control of spontaneous and induced immunity to Friend murine retrovirus infection. Annu Rev Immunol 1990, 8:477-499.
222. Eiden MV, Farrell K, Warsowe J, Mahan LC, Wilson CA: Characterization of a naturally occurring ecotropic receptor that does not facilitate entry of all ecotropic murine retroviruses. J Virol 1993, 67:4056-4061.
223. Kozak CA: Susceptibility of wild mouse cells to exogenous infection with xenotropic leukemia viruses: control by a single dominant locus on chromosome 1. J Virol 1985, 55:690-695.
224. Marin M, Tailor CS, Nouri A, Kozak SL, Kabat D: Polymorphisms of the cell surface receptor control mouse susceptibilities to xenotropic and polytropic leukemia viruses. J Virol 1999, 73:9362-9368.
225. Ikeda H, Laigret F, Martin MA, Repaske R: Characterization of a molecularly cloned retroviral sequence associated with Fv-4 resistance. J Virol 1985, 55:768-777.
226. Taylor GM, Gao Y, Sanders DA: Fv-4: identification of the defect in Env and the mechanism of resistance to ecotropic murine leukemia virus. J Virol 2001, 75:11244-11248.
227. Suzuki S: FV-4: a new gene affecting the splenomegaly induction by Friend leukemia virus. Jpn J Exp Med 1975, 45:473-478.
228. Ruscetti S, Davis L, Feild J, Oliff A: Friend murine leukemia virus-induced leukemia is associated with the formation of mink cell focus-inducing viruses and is blocked in mice expressing endogenous mink cell focus-inducing xenotropic viral envelope genes. J Exp Med 1981, 154:907-920.
229. Hartley JW, Yetter RA, Morse 3rd HC: A mouse gene on chromosome 5 that restricts infectivity of mink cell focus-forming recombinant murine leukemia viruses. J Exp Med 1983, 158:16-24.
230. Jolicoeur P: The Fv-1 gene of the mouse and its control of murine leukemia virus replication. Curr Top Microbiol Immunol 1979, 86:67-122.
231. Stoye JP: Fv1, the mouse retrovirus resistance gene. Rev Sci Tech 1998, 17:269-277.
232. Best S, Le Tissier P, Towers G, Stoye JP: Positional cloning of the mouse retrovirus restriction gene Fv1. Nature 1996, 382:826-829.
233. Benit L, De Parseval N, Casella JF, Callebaut I, Cordonnier A, Heidmann T: Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERV-L element and with a gag coding sequence closely related to the Fv1 restriction gene. J Virol 1997, 71:5652-5657.
234. Rommelaere J, Donis-Keller H, Hopkins N: RNA sequencing provides evidence for allelism of determinants of the N-, B- or NB-tropism of murine leukemia viruses. Cell 1979, 16:43-50.
235. Hopkins N, Schindler J, Hynes R: Six-NB-tropic murine leukemia viruses derived from a B-tropic virus of BALB/c have altered p30. J Virol 1977, 21:309-318.
236. DesGroseillers L, Jolicoeur P: Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J Virol 1983, 48:685-696.
237. Kozak CA, Chakraborti A: Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology 1996, 225:300-305.
238. Boone LR, Innes CL, Heitman CK: Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J Virol 1990, 64:3376-3381.
239. Goff SP: Operating under a Gag order: a block against incoming virus by the Fv1 gene. Cell 1996, 86:691-693.
240. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP, Danos O: A conserved mechanism of retrovirus restriction in mammals. Proc Natl Acad Sci U S A 2000, 97:12295-12299.
241. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ: Restriction of multiple divergent retroviruses by Lv1 and Ref1. Embo J 2003, 22:385-394.
242. Besnier C, Ylinen L, Strange B, Lister A, Takeuchi Y, Goff SP, Towers GJ: Characterization of murine leukemia virus restriction in mammals. J Virol 2003, 77:13403-13406.
243. Towers G, Collins M, Takeuchi Y: Abrogation of of Ref1 retrvirus restriction in human cells J Virol 2002,76:2548-2550.
244. Franke EK, Yuan HE, Luban J: Specific incorporation f cyclophilin A into HIV-virions. Nature 1994, 372:359-362.
245. Cowan S, Hatziionnau T, Cunningham T, Muesing MA, Gottlinger HG, Bienias PD: Cellular inhibitors with Fv1-like activity restrict human and simain immuneodeficiency virus tropism. Proc Natl Acad Sci U S A 2002, 99:11914-11919.
246. Besnier C, Takeuchi Y, Towers G: Restriction of lentivirus in monkeys. Proc Natl Acad Sci U S A 2002, 99:11920-11925.
247. Munk C, Brandt SM, Lucero G, Landau N: A dominant block to HIV-1 replication at reverse transcrition in simian cells. Proc Natl Acad Sci U S A 2002, 99:13843-13848.
248. Schmitz C, Marchant D, Neil SJD, Aubin K, Reuter S, Dittmar MT, McKnight A: Lv2, a novel postentry restrictionis indicated by both capsid and envelope. J Virol 2004, 78:2006-206.
249. McKnight A, Griffiths DJ, Dittmar M, Clapham P, Thomas E: Characterization of a late entry event inthe replication cycle of human immunodeficiency virus type 2. J Virol 2001, 75:6914-6922.
250. Stremlau M, Owens CM, Perron MJ, Kiessling, Autissier P, Sodroski J: The cytoplasmic body component TRIM5a restricts HIV-1 infection in Old World monkeys. Nature 2004, 427:848-853.
251. Regad T, Chelbi-Alix MK: Role and faith of PML nuclear bodies in response to interferon and viral infections. Oncogene 2001, 20:7274-7286.
252. Muranyi W, Flugel RM: Analysis of splicing patterns of human spumaretrovirus by plymerase chain reactions reveals complex RNA structures. J Virol 1991, 65:727-735.
253. Lecellier CH, Vermueelen W, Bachelerie F, Giron ML, Saib A: Intra- and intercellular trafficking of the foamy virus auxiliary bet protien. J Virol 2002, 76:3388-3394
254. Giron ML, de The H, Saib A: An evolutionary conserved splice generates a secreted env-Bet fusion protien during human foamy virus infection. J Virol 1998,72:4906-4910.
255. Saib A, Koken MH, van der Spek P, Peries de The H: Involvemen of a spliced and defective human foamy virus in the establishment of chronic infection. J Virol 1995 69:5261-5268.
256. Bock M, Heinkelein , Linderman D, Rethwilm A: cells expressing the human foamy virus (HFV) accessory Bet protien are resistant to prodctive HFV superinfection. Virology 1998, 250:194-204.
257. Miering CD, Linial ML: Reactivation of complex retrovirus is controlled by a molecular switch and is inhibited by a viral protien. Proc Natl Acad Sci U S A 2002,99:15130-15135.
258. Nagy K, Young M, Baboonian C, Merson J, Whittle P, Oroszlan S: Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J Virol 1994, 68:757-765.
259. Toszer J, Shulenin S, Kadas J, Boross P, Bagossi P, Copeland TD, Nair BC, Sarngadharan MG, Oroszlan S: Human immunodeficiency virus type 1 capsid protien is a subtrate of the rertoviral protienase while integrase is resistant toward proteolysis. Virology 2003, 310:16-23.
260. Romluva M, Ruml T, Pohl J, Pichova I: Specific in vitro cleavage of Mason-Pfizer mnkey virus capsid protien: evidence for a potential role of retroviral protease in early stages of infection. Virology 2003, 310:310-318.
261. Greber UF, Webster P, Weber J, Helenius A: The role of the adenovirus protease on virus entry into cells. Embo J 1996, 15:1766-1777.
262. Kinet S, Bernad F, Mongellaz C, Perreau M, Goldman Fd, Taylor N: gp120-mediated induction of the MAPK cascade is dependent on the activition state df CD4(+) lymphocytes. Blood 2002, 100:2546-2553.
263. Greber UF: Signalling in viral entry. Cell Mol Life Sci 2002, 59:608-626.
264. Persaud D, Zhou Y, Siliciano JM, Siliciano RF: Latency in human immundeficiency virus type 1 infetion: no easy answers. J Virol 2003, 77:1659-1665.
265. Persaud D, Pierson T, Ruff C, Finzi D, Chadwick KR, Margolick JB, Ruff A, Hutton N, Ray S, Siliciano RF: A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000, 105:995-1003.